Increasing incidence is fuelling the Hepatocellular Carcinoma Market




The most common form of primary liver cancer, Hepatocellular Carcinoma (HCC) is a malignant tumour of hepatocytes.
Increasing Hepatocellular Carcinoma (HCC) Incidence
Hepatocellular Carcinoma incidence is growing worldwide because of the dissemination of Hepatitis B and C virus infection making it the fifth most common cause of cancer.
 Hepatocellular cell carcinoma is found to be more common in males as compared to females. 
Moreover, 70%–90% of HCC patients have a previous history of chronic liver disease and cirrhosis.
This indicates their chances of being diagnosed with chronic infection with hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease, and non-alcoholic steatohepatitis (NASH).
According to DelveInsight, a healthcare business consulting firm, the total HCC incident cases in G8 countries estimated to be around 4,58,170 in 2016.  
On the other hand, the total Diagnosed Advanced Hepatocellular Carcinoma cases in G8 countries around 1, 60,565 cases and the numbers are expected to increase in the coming years.
Moreover, DelveInsight estimates that the total HCC patients in G8 countries on first- and second-line therapies were 39,224 and 14,215, respectively.
Increasing Hepatocellular Carcinoma therapy market 
Opdivo developed by Bristol-Myers Squibb is approved only in the US and Stivarga, again a Bayer’s therapy got FDA recommendation in 2017 itself. Both of the treatments have created a positive impact on the Hepatocellular Carcinoma market size.
Other Hepatocellular Carcinoma therapies include Miripla [Miriplatin, Dainippon Sumitomo Pharma], and Lenvima which got approved only in Japan. 
Booming Hepatocellular Carcinoma market 
Hepatocellular Carcinoma Market analysis demonstrates that the HCC Market size was about USD 723.4 million in 2016 in G8 countries.
DelveInsight estimates that the United States had the highest Hepatocellular Carcinoma market share in 2016, as compared to EU5 (Germany, France, Italy, Spain & UK) Japan and China. Among EU5, Italy has the highest Hepatocellular market, while the UK had the lowest HCC market.
At present, the Hepatocellular Carcinoma therapeutic market size is mainly accounted for by the protein Kinase inhibitor, i.e., Nexavar (Sorafenib), a product of Bayer.
Hepatocellular Carcinoma Emerging Drugs Analysis
The dynamics of Hepatocellular Carcinoma market is anticipated to change in the coming years owing to the expected launch of therapies.
There are presently three emerging therapies focused on the treatment of HCC- Ramucirumab (Eli Lilly; 2nd Line of Therapy), Cabozantinib (Exelixis; 2nd Line of Therapy), and Lenvima (Eisai Pharmaceuticals & Merck; 1st Line of therapy).


Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more